Study shows
Reyataz has low failure rate

A lower percentage of HIV patients taking Reyataz experienced a rebound in viral levels compared with patients on other protease inhibitors, according to an announcement from Bristol-Myers Squibb, the manufacturer of Reyataz. The study of 419 patients found that 7% of those who switched to Reyataz experienced increasing viral levels, compared with 16% of patients who continued on other protease inhibitors. The company did not identify the other protease inhibitors. (AP)